Drug Profile

Lerodalcibep - LIB Therapeutics

Alternative Names: HST 101; LeroChol; LIB-003

Latest Information Update: 11 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LIB Therapeutics
Developer Hasten Biopharmaceutic; LIB Therapeutics
Class Antihyperlipidaemics; Recombinant fusion proteins
Mechanism of Action PCSK9 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preregistration Hypercholesterolaemia

Most Recent Events

03 Aug 2025 LIB Therapeutics plans the phase IIIb LIBerate Kids trial for Hypercholesterolemia (In children, In adolescents, Treatment experienced) in USA, South Africa and Turkey (SC) (NCT07102511)
14 Feb 2025 LIB Therapeutics intends to launch lerodalcibep for hypercholesterolemia in USA
11 Feb 2025 Preregistration for Hypercholesterolaemia in USA (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com